Anebulo Pharmaceuticals, Inc.
ANEB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,300 | $3,549 | $5,600 | $2,962 |
| G&A Expenses | $0 | $4,755 | $0 | $0 |
| SG&A Expenses | $4,924 | $4,760 | $6,183 | $3,870 |
| Sales & Mktg Exp. | $0 | $5 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,223 | $8,309 | $11,784 | $6,831 |
| Operating Income | -$9,223 | -$8,309 | -$11,784 | -$6,831 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $739 | $107 | $51 | $6 |
| Pre-Tax Income | -$8,485 | -$8,202 | -$11,732 | -$6,826 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,485 | -$8,202 | -$11,732 | -$6,826 |
| % Margin | – | – | – | – |
| EPS | -0.25 | -0.32 | -0.47 | -0.29 |
| % Growth | 21.9% | 31.9% | -62.1% | – |
| EPS Diluted | -0.25 | -0.32 | -0.47 | -0.29 |
| Weighted Avg Shares Out | 33,820 | 25,822 | 25,074 | 23,345 |
| Weighted Avg Shares Out Dil | 33,820 | 25,822 | 25,074 | 23,345 |
| Supplemental Information | – | – | – | – |
| Interest Income | $258 | $249 | $92 | $7 |
| Interest Expense | $382 | $151 | $0 | $0 |
| Depreciation & Amortization | $0 | $258 | $0 | $0 |
| EBITDA | -$8,103 | -$7,792 | -$11,732 | -$6,826 |
| % Margin | – | – | – | – |